Group 1 - The underwriter of Averin Capital Acquisition Corp.'s initial public offering has partially exercised its option to purchase an additional 3,386,008 units at a price of $10.00 per unit, generating approximately $33,860,080 in additional gross proceeds [1] - Following this partial exercise, the total number of units sold in the public offering has increased to 28,386,008 units, resulting in total gross proceeds of $283,860,080 for the offering [2] - Each unit consists of one Class A ordinary share and one-sixth of one redeemable warrant, with each whole warrant allowing the holder to purchase one Class A ordinary share at a price of $11.50 per share [3] Group 2 - The registration statement for the securities was filed with the U.S. Securities and Exchange Commission and became effective on February 18, 2026 [4] - Deutsche Bank Securities Inc. acted as the sole book-running manager for the offering [3]

Core Viewpoint - Averin Capital Acquisition Corp. successfully closed its initial public offering (IPO) of 25,000,000 units, generating gross proceeds of $250,000,000 at a price of $10.00 per unit [1][2]. Group 1: IPO Details - The units began trading on February 19, 2026, on the Nasdaq under the ticker symbol "ACAAU" [2]. - Each unit consists of one Class A ordinary share and one-sixth of a redeemable warrant, with the whole warrant allowing the purchase of one Class A ordinary share at an exercise price of $11.50 [2]. - The underwriter has a 45-day option to purchase an additional 3,750,000 units at the IPO price to cover over-allotments [2]. Group 2: Financial Proceeds - From the IPO and a simultaneous private placement, $2,000,000 (or $10.00 per unit sold) was placed in trust [3]. Group 3: Company Purpose and Management - The company is a blank check entity aimed at merging or acquiring businesses, focusing on the intersection of technology and health industries [4]. - The management team includes David Berry as CEO and Chairman, and Alex Lau as CFO, with additional board members Ulrik Schulze, Graeme Bell, and Mary T. Szela [5]. Group 4: Regulatory Information - A registration statement for the securities was declared effective by the U.S. Securities and Exchange Commission on February 18, 2026 [6].

Company Overview - Averin Capital Acquisition Corp. is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily focusing on opportunities in the technology and health industries [2]. IPO Details - The company announced the pricing of its initial public offering (IPO) of 25,000,000 units at a price of $10.00 per unit, with units expected to be listed on the Nasdaq Global Market under the ticker symbol "ACAAU" starting February 19, 2026 [1]. - Each unit consists of one Class A ordinary share and one-sixth of one redeemable warrant, with each whole warrant allowing the holder to purchase one Class A ordinary share at a price of $11.50 per share [1]. - An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering, which is expected to close on February 20, 2026, subject to customary closing conditions [1]. - The underwriters have been granted a 45-day option to purchase up to an additional 3,750,000 units at the initial public offering price to cover over-allotments [1]. Management Team - The management team is led by David A. Berry as Chairman and Chief Executive Officer, and Alex Lau as Chief Financial Officer and Secretary. The Board of Directors includes Ulrik Schulze, Graeme Bell, and Mary T. Szela [3]. Underwriting - Deutsche Bank Securities Inc. is acting as the sole book-running manager for the offering [3]. Regulatory Information - A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on February 18, 2026 [5]. - The offering is being made only by means of a prospectus, which can be obtained from Deutsche Bank Securities Inc. or accessed via the SEC's website [4].

As filed with the U.S. Securities and Exchange Commission on January 30, 2026. Registration No. 333-[•] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________ FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _____________________________________ Averin Capital Acquisition Corp. (Exact name of registrant as specified in its charter) _____________________________________ Cayman Islands 6770 98-1891461 (State or other jurisdiction of incorp ...